Cladribine

Under new CEO Kai Beckmann, Merck KGaA is emphasizing M&A to stock its early- to mid-stage pharma pipeline, the company said in reporting its first quarter results on Wednesday. Merck KGaA made its largest acquisition in a decade in April 2025, when it snapped up Connecticut rare disease specialist SpringWorks Therapeutics for $3.9 billion. A year later, as the German conglomerate presented its first-quarter earnings, it reiterated its focus on M&A, largely to fuel its pharma pipeline.“We will broaden our M&A scope,” new CEO Kai Beckmann said during a conference call.In laying out the company’s business update (PDF), Beckmann said M&A is a growth lever that is “critical” for innovation and that acquiring external innovation is needed to build a risk-balanced pharma pipeline.“By combining our core strengths in biology, chemistry and physics with data and AI, we will become a more agile company that delivers at greater speed and scale,” Beckmann said.While Merck KGaA has three unrelated phase 3 programs, the company’s Healthcare CEO, Danny Bar Zohar, called its early- to midstage pipeline “rather slim.”“We need to build that in order to sustain, or to ensure, that we grow beyond that low-to-mid single-digit mid-term guidance that we gave you beyond 2030, beyond 2031,” Bar Zohar said. “This is something that we need to start building now.” After the 2024 failure of BTK inhibitor evobrutinib, Merck KGaA is relying heavily on a trio of late-stage oncology assets, including pimicotinib, which is under review by the FDA, and antibody-drug conjugate precemtabart tocentecan. The company is also pointing to a second-half launch in the U.S. of the fertility drug Pergoveris, which is being assessed under the FDA’s new Commissioner’s National Priority Review Voucher (CNPV) program.Merck KGaA reported first-quarter sales of 5.1 billion euros, down from 5.3 billion euros in the same period last year. Healthcare sales fell 3%, driven largely by a 5% decline in oncology product sales and a 9% drop in neurology and immunology treatment sales. That segment includes multiple sclerosis drug Mavenclad, which posted a 7% sales decline. The company raised its revenue projection by 10 million euros at the midpoint of its guidance range, as competition for Mavenclad is expected to arrive two months later than previously anticipated. The company also attributed a 16% increase in Process Solutions revenue to stockpiling of lab supplies by clients anticipating supply chain disruptions tied to the war in Iran.With the upgraded guidance, Merck KGaA’s share price increased by 8%.

EHA 2026 The European Hematology Association 2026年欧洲血液学协会年会（EHA 2026）将于6月11日至14日在瑞典斯德哥尔摩盛大召开。作为全球血液领域极具权威性与影响力的顶尖学术盛会，本届大会汇聚全球血液学领域权威专家、科研学者与临床医师，共享前沿进展，共探学科未来。 微芯生物全球首创药物西达本胺（爱谱沙®）多个领域17项研究将于EHA 2026公布，包括8项壁报，9项在线摘要，全面呈现中国原创表观遗传调控药物在血液肿瘤领域的临床价值与创新潜力。 非霍奇金性淋巴瘤（NHL） 1项 1 研究名称：西达本胺、克拉屈滨、吉西他滨联合白消安作为预处理方案与BEAM方案用于高危非霍奇金淋巴瘤的比较：一项倾向性评分匹配分析 英文题目：Comparison Between Chidamide, Cladribine, Gemcitabine and Busulfan as Conditioning Regimen and BEAM for High Risk Non-Hodgkin Lymphoma: A Propensity Score Match Analysis 摘要编号：PS2233 报告类型：Poster Presentation 第一作者：邝璞 通讯作者：季杰 四川大学华西医院 T细胞淋巴瘤（TCL）6项 1 研究名称：抗PD-1抗体联合西达本胺、来那度胺和依托泊苷治疗复发/难治性结外NK/T细胞淋巴瘤（鼻型）：一项前瞻性、多中心、单臂试验 英文题目：Anti-PD-1-Antibody (Tislelizumab) Plus Chidamide, Lenalidomide and Etoposide for Refractory/Relapsed Extranodal NK/T-Cell Lymphoma, Nasal Type: A Prospective, Multicenter, Single-Arm Trial 摘要编号：PS2131 报告类型：Poster Presentation 第一作者：常宇 通讯作者：张明智 郑州大学第一附属医院 2 研究名称：戈利昔替尼联合阿扎胞苷及西达本胺治疗外周T细胞淋巴瘤的安全性和疗效：一项开放标签、单臂研究 英文题目：Safety and Efficacy of Golidocitinib in Combination with Azacitidine and Chidamide for the Treatment of Peripheral T-Cell Lymphoma: An Open-Label, Single-Arm Study 摘要编号：PB3862 报告类型：Publication Only 第一作者：程澍 通讯作者：程澍 上海交通大学医学院附属瑞金医院 3 研究名称：维布妥昔单抗联合西达本胺治疗CD30阳性皮肤T细胞淋巴瘤的疗效和安全性：一项正在进行中的多中心、开放标签、单队列研究方案 英文题目：Efficacy and Safety of Brentuximab Vedotin with Chidamide in CD30-Positive Cutaneous T-Cell Lymphoma: A Multicenter, Open-Label, Single-Cohort Study Protocol in Progress 摘要编号：PB3893 报告类型： Publication Only 第一作者：王倩 通讯作者：陈彤 复旦大学附属华山医院 4 研究名称：维布妥昔单抗联合西达本胺及盐酸米托蒽醌脂质体或戈利昔替尼治疗复发/难治性CD30阳性皮肤T细胞淋巴瘤：一项真实世界研究 英文题目：Brentuximab Vedotin Combined with Chidamide and Mitoxantrone Hydrochloride Liposome or Golidocitinib in Relapsed/Refractory CD30-Positive Cutaneous T-Cell Lymphoma: A Real-World Study 摘要编号：PB3906 报告类型：Publication Only 第一作者：王倩 通讯作者：陈彤 复旦大学附属华山医院 5 研究名称：戈利昔替尼、盐酸米托蒽醌脂质体、西达本胺和泼尼松（GO-MCP方案）治疗复发/难治性外周T细胞淋巴瘤：一项真实世界回顾性研究 英文题目：Golidocitinib, Mitoxantrone Hydrochloride Liposome, Chidamide and Prednisone (GO-MCP) in Relapsed/Refractory Peripheral T-Cell Lymphoma: A Real-World Retrospective Study 摘要编号：PB3902 报告类型：Publication Only 第一作者：葛峥 通讯作者：葛峥 东南大学附属中大医院 6 研究名称：双表观遗传治疗在初诊血管免疫母细胞性T细胞淋巴瘤的高龄患者（>70岁）中显示出令人鼓舞的疗效 英文题目：Promising Outcomes with Dual Epigenetic Therapy for Older Patients (>70 Years) with Newly Diagnosed Angioimmunoblastic T-Cell Lymphoma 摘要编号：PB3982 报告类型：Publication Only 第一作者：杨春梅 通讯作者：金洁 浙江大学医学院附属第一医院 急性髓细胞性白血病&骨髓增生异常综合征（AML&MDS） 6项 1 研究名称：西达本胺联合维奈克拉及阿扎胞苷（VAC）对比VA方案治疗初诊免疫表型成熟单核细胞AML：一项多中心随机研究的最新分析 英文题目：Chidamide Plus Venetoclax and Azacitidine (VAC) versus VA Regimen in Newly Diagnosed Immunophenotypically Mature Monocytic AML: An Updated Analysis from a Multicenter Randomized Study 摘要编号：PF490 报告类型：Poster Presentation 第一作者：谭恺文 通讯作者：薛胜利 苏州大学第一附属医院 2 研究名称：西达本胺联合阿扎胞苷双表观遗传靶向治疗异基因造血干细胞移植后高危急性髓系白血病患者的II期研究最新结果 英文题目：Updated Results from the Phase II Study of Dual Epigenetic Targeting with Chidamide and Azacitidine in Patients with High Risk Acute Myeloid Leukemia after Allo-HSCT 摘要编号：PF393 报告类型：Poster Presentation 第一作者：胡晓慧 通讯作者：胡晓慧 苏州大学附属第一医院 3 研究名称：维奈克拉－阿扎胞苷－西达本胺联合CAG方案作为诱导化疗用于骨髓增生异常相关急性髓系白血病 英文题目：Venetoclax-Azacitidine-Chidamide Plus CAG As Induction Chemotherapy For Myelodysplasia-Related Acute Myeloid Leukemia 摘要编号：PF556 报告类型：Poster Presentation 第一作者：刘青阳 通讯作者：窦立萍 中国人民解放军总医院 4 研究名称：维奈克拉-阿扎胞苷联合西达本胺及CAG方案对比“3+7”方案用于适合强化治疗的初诊急性髓系白血病老年患者：一项多中心、随机、III期试验 英文题目：Venetoclax-Azacitidine in Combination with Chidamide and CAG versus "3+7" Regimen in Fit Older Patients with Newly Diagnosed Acute Myeloid Leukemia: A Multicenter, Randomized, Phase 3 Trial 摘要编号：PS1590 报告类型：Poster Presentation 第一作者：谷振阳 通讯作者：窦立萍 中国人民解放军总医院 5 研究名称：多组学浆细胞样树突状细胞特征可预测急性髓系白血病的预后并优化风险分层 英文题目：A multi-omics plasmacytoid dendritic cell signature predicts prognosis and refines risk stratification in acute myeloid leukemia 摘要编号：PS1581 报告类型：Poster Presentation 第一作者：文萱 通讯作者：杜欣、翁建宇、黄欣等，广东省人民医院 6 研究名称：脂质体米托蒽醌联合维奈克拉、阿扎胞苷和西达本胺（VACM方案）治疗急性单核细胞白血病的疗效和安全性 英文题目：Efficacy and Safety of Liposomal Mitoxantrone Combined with Venetoclax, Azacitidine, and Chidamide (VACM) in Acute Monocytic Leukemia 摘要编号：PB2800 报告类型：Publication Only 第一作者：谢黛荣 通讯作者：谢黛荣 华中科技大学同济医学院附属协和医院血液病学研究所 急性淋巴细胞白血病（ALL）1项 1 研究名称：基于西达本胺的强化预处理方案在异基因造血干细胞移植治疗T细胞急性淋巴细胞白血病/淋巴瘤患者中的安全性和疗效 英文题目：Safety and Efficacy of Chidamide-Based Intensified Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation in Patients with T-Cell Acute Lymphoblastic Leukemia/Lymphoma 摘要编号：PB2604 报告类型：Publication Only 第一作者：葛东雪 通讯作者：葛东雪 中国人民解放军总医院 基础研究  3项 1 研究名称：HDAC抑制剂西达本胺联合GL-V9通过抑制MYBL2表达在急性髓系白血病中的协同疗效 英文题目：Synergistic Efficacy of HDACi Chidamide with GL-V9 by Suppressing MYBL2 Expression in Acute Myeloid Leukemia 摘要编号：PS1586 报告类型：Poster Presentation 第一作者：葛峥 通讯作者：葛峥 东南大学 2 研究名称：戈利昔替尼联合西达本胺治疗外周T细胞淋巴瘤：在抑制肿瘤增殖和调节免疫微环境中的可能机制及治疗潜力 英文题目：Combination of Golidocitinib with Chidamide for Peripheral T-Cell Lymphoma: Possible Mechanisms and Therapeutic Potential in Inhibiting Tumor Proliferation and Modulating the Immune Microenvironment 摘要编号：PB3926 报告类型：Publication Only 第一作者：李莉 通讯作者：李莉 大连医科大学附属第二医院 3 研究名称：B细胞急性淋巴细胞白血病中一种新IKZF1突变的致癌作用及药物敏感性 英文题目：Oncogenic Role and Drug Sensitivity of a New IKZF1 Mutation in B-Cell Acute Lymphoblastic Leukemia 摘要编号：PB2541 报告类型：Publication Only 第一作者：葛峥 通讯作者：葛峥 东南大学附属中大医院 微芯生物在血液肿瘤领域持续深耕二十余年，始终以患者需求为导向，不断产出具有国际影响力的高质量成果，推动并见证中国血液肿瘤走向世界的坚实步伐。西达本胺学术积累加速转化为全球认可，2025年共有48项研究成果入选顶级全球学术大会。 西达本胺联合R-CHOP序贯单药维持一线治疗DE-DLBCL的方案，作为全球首个在III期临床中显著提升完全缓解率的创新方案，为患者建立了全新一线治疗标准，成为全球该领域里程碑式突破。 凭借持续深耕，西达本胺从外周T细胞淋巴瘤出发，逐步构建起覆盖淋巴瘤到实体肿瘤的跨领域治疗版图，并确立了在血液肿瘤领域的独特治疗地位。 关于西达本胺（爱谱沙®） 西达本胺（Chidamide；商品名：爱谱沙®/Epidaza®）是全球首个亚型选择性组蛋白去乙酰化酶（HDAC）抑制剂、中国首个原创抗肿瘤化学新药。该药属于表观遗传调控类药物，对肿瘤抑制性免疫微环境具有重新激活作用，可单独或联合其他药物治疗恶性肿瘤，应用前景广阔。 西达本胺已纳入国家医保药品目录常规乙类管理。在中国（涵盖大陆、澳门及台湾地区）已获批外周T细胞淋巴瘤、乳腺癌、弥漫大B细胞淋巴瘤3个适应症；在日本获批成人T细胞白血病和外周T细胞淋巴瘤。 与此同时，西达本胺正全面推进纵深管线，在中国及海外开展滤泡辅助T细胞表型外周T细胞淋巴瘤III期、结直肠癌III期、黑色素瘤III期等多项临床研究，其联合肿瘤免疫疗法（HDACi+IO）的策略在多个瘤种中持续验证，下一代HDACi+IO药物也正在开发中。 往期推荐 西达本胺DEB研究结果荣登JAMA ASCO 2026抢先看！ 白皮书预告